Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

38.02
-0.9100-2.34%
Post-market: 37.28-0.7400-1.95%19:30 EDT
Volume:1.94M
Turnover:73.46M
Market Cap:3.67B
PE:-8.08
High:39.10
Open:39.10
Low:37.26
Close:38.93
52wk High:72.66
52wk Low:36.07
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.70
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:2.96
PE(LYR):-8.71

Loading ...

【US Pre-Market】US Stock Futures Mixed on Triple Witching; Optical Communication, Storage, and Crypto Stocks Gain as WTI Crude Plunges Over 5%

TradingKey
·
Sep 18

Top Premarket Decliners

MT Newswires Live
·
Sep 18

U.S. Stocks on the MOVE-Netflix, Etsy, Viant Technology

Reuters
·
Sep 18

Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword

Dow Jones
·
Sep 18

S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag

Dow Jones
·
Sep 18

Xenon Pharmaceuticals Price Target Cut to $90.00/Share from $97.00 by Baird

Dow Jones
·
Sep 18

Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird

TIPRANKS
·
Sep 18

Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90

THOMSON REUTERS
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

TIPRANKS
·
Sep 18

Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90

MT Newswires Live
·
Sep 18

Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials

THOMSON REUTERS
·
Sep 18

Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81

THOMSON REUTERS
·
Sep 18

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

Dow Jones
·
Sep 18

Xenon Pauses New Enrollment in Depression, Bipolar Disorder Trials over Side-Effect Concerns

Reuters
·
Sep 18

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Reuters
·
Sep 18

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Reuters
·
Sep 18

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS
·
Sep 18

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS
·
Sep 18

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS
·
Sep 18

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS
·
Sep 18